This week we finish our analysis of our GLP-1 survey results with a look at prescribing reasons and habits, and how your colleagues decide on GLP-1 analog or DPP-4 inhibitor therapy. Most of the respondents favored Victoza but not as by as wide a margin as expected. Prescribers had a more even split as to which GLP1-Agonist they preferred than non-prescribers. The most common comment was that the once a day dosing of Victoza was a big advantage….
We would like to thank all our readers who took the time to participate in this survey, helping us gain insight into how you think and put into practice your knowledge of GLP-1 Agonists.
Click below to access other articles in this series:
GLP-1 Knowledge Survey, Part VI
Copyright © 2011 Diabetes In Control, Inc.